Systematic Review of Reduning Injection in Treatment of Hand-foot-mouth Disease

WANG Xuan; XU Jing; XU Jin; HE Xin; ZHANG Yong

doi:10.13422/j.cnki.syfjx.2016190171

您当前的位置：

首页 >

文章列表页 >

Systematic Review of Reduning Injection in Treatment of Hand-foot-mouth Disease

更新时间：2024-01-04

- Systematic Review of Reduning Injection in Treatment of Hand-foot-mouth Disease
- Chinese Journal of Experimental Traditional Medical Formulae Vol. 22, Issue 19, Pages: 171-176(2016)
- 作者机构：
- 作者简介：
- 基金信息：
- DOI：10.13422/j.cnki.syfjx.2016190171
  CLC： R272
- Published：2016
- 稿件说明：
移动端阅览
WANG Xuan, XU Jing, XU Jin, et al. Systematic Review of Reduning Injection in Treatment of Hand-foot-mouth Disease[J]. Chinese journal of experimental traditional medical formulae, 2016, 22(19): 171-176.
DOI：

WANG Xuan, XU Jing, XU Jin, et al. Systematic Review of Reduning Injection in Treatment of Hand-foot-mouth Disease[J]. Chinese journal of experimental traditional medical formulae, 2016, 22(19): 171-176. DOI： 10.13422/j.cnki.syfjx.2016190171.

摘要

目的：系统评价热毒宁注射液治疗手足口病的临床疗效及安全性，为临床治疗提供循证参考。方法：采用Cochrane系统评价方法，全面检索Cochrane Library，CBM，CNKI

Wanfang等数据库，查找热毒宁注射液治疗手足口病相关的随机对照试验（RCT），采用RevMan 5.2软件进行Meta分析。结果：共24项随机对照研究符合纳入标准，其中热毒宁VS利巴韦林17项，合计2 412例患者，热毒宁联合利巴韦林VS利巴韦林7项，合计891例患者。Meta分析结果显示，与利巴韦林相比，热毒宁治疗手足口病的临床总有效率更高[OR=4.71，95% CI（3.46，6.42），P<0.000 01]，退热时间[WMD=-1.20，95% CI（-1.44，-0.95），P<0.000 01]，皮疹消退时间[WMD=-1.51，95% CI（-1.95，-1.07），P<0.000 01]，口腔疱疹或溃疡消退时间[WMD=-1.36，95% CI（-1.76，-0.97），P<0.000 01]，平均住院时间[WMD=-2.81，95% CI（-3.79，-1.82），P<0.000 01]均短于利巴韦林，差异均具有统计学意义。与利巴韦林单药治疗相比，热毒宁与利巴韦林联合用药在临床总有效率[OR=5.48，95% CI（3.06，9.80），P<0.000 01]，退热时间[WMD=-1.70，95% CI（-2.05，-1.35），P<0.000 01]，皮疹消退时间[WMD=-1.91，95% CI（-2.99，-0.83），P<0.000 01]，口腔疱疹或溃疡消退时间[WMD=-1.81，95% CI（-2.09，-1.53），P<0.000 01]，平均住院时间[WMD=-2.32，95% CI（-3.59，-1.05），P=0.000 3]更有优势，差异均具有统计学意义。纳入的24项研究中热毒宁的不良反应较利巴韦林表现轻微，使用更为安全。结论：当前证据表明热毒宁联用利巴韦林与单用热毒宁治疗手足口病的疗效优于单用利巴韦林，且安全性良好。但由于纳入的研究质量有限，尚需设计更多大样本、高质量的临床试验进一步验证。

Abstract

Objective: To systematically review the efficacy and safety of Reduning injection for treating hand-foot-mouth disease (HFMD). Method: The Cochrane system evaluation method was used to retrieve such databases as the Cochrane Library

CBM

CNKI and Wanfang Data to collect the randomized controlled trials of Reduning injection in treating HFMD. The meta-analysis was performed using RevMan 5.2 software. Result: The 17 RCTs on Reduning versus Ribavirin involving 2 412 cases

as well as 7 RCTs on Reduning combined with Ribavirin involving 891 cases were included. The results of the Meta-analysis showed that the total treatment efficiency of Reduning group was better than that of Ribavirin[OR=4.71

95%CI (3.46

6.42)

P<0.000 01]

with a shorter fever clearance time[WMD=-1.20

95%CI (-1.44

-0.95)

P<0.000 01]

skin rash regression time[WMD=-1.51

95%CI (-1.95

-1.07)

P<0.000 01]

oral herpes or ulcer regression time[WMD=-1.36

95%CI (-1.76

-0.97)

P<0.000 01]and hospitalization time[WMD=-2.81

95%CI (-3.79

-1.82)

P<0.000 01]

and significant differences. Compared to the Ribavirin group

the group of Reduning combined with Ribavirin was superior than the control group in the total treatment efficiency[OR=5.48

95%CI (3.06

9.80)

P<0.000 01]

fever clearance time[WMD=-1.70

95%CI (-2.05

-1.35)

P<0.000 01]

skin rash regression time[WMD=-1.91

95%CI(-2.99

-0.83)

P<0.000 01]

oral herpes or ulcer regression time[WMD=-1.81

95%CI(-2.09

-1.53)

P<0.000 01]and hospitalization time[WMD=-2.32

95%CI (-3.59

-1.05)

P=0.000 3]

with significant differences. The 24 reports showed that the ADR/ADE of Reduning were lighter than that of Ribavirin

with a higher safety. Conclusion: Actual clinical evidence indicated that the efficacy and safety of the administration with Reduning alone and Reduning combined with Ribavirin was better than the administration with Ribavirin alone in the treatment of HFMD. However

because the reliability of systematic review is restricted by low quality of included study

more high-quality

large-scale and multiple-centered randomized controlled trials should be carried out for further verifying the conclusion.

关键词

Keywords

references

Views

下载量

CSCD

Alert me when the article has been cited

提交

Tools

Publicity Resources

Meta-analysis and Grade Evidence Evaluation of Qi-reinforcing and Blood-activating/ Stasis-expelling Chinese Patent Medicines in Treatment of Coronary Microvascular Disease

Efficacy and Safety of Modified Qingjin Huatantang Combined with Western Medicine in Treatment of Phlegm-heat： A Systematic Review and Meta-analysis

Efficacy and Safety of Spleen-strengthening Therapy in Treatment of Postoperative Colorectal Adenoma： A Meta-analysis

Systematic Review and Meta-analysis of Hexue Mingmu Tablets in Treatment of Diabetic Retinopathy and Retinal Vein Obstruction

Effect of Reduning Injection， Shenfu Injection Combined with Gefitinib on Proliferation， Stemness Characteristics and Metabolism of Non-small Cell Lung Cancer Cells

Related Author

CHEN Jiaping

SHANG Juju

LIU Hongxu

LI Xiang

LAI Xiaolei

ZHOU Huiwen

WANG Lu

WANG Jiajia

Related Institution

Beijing Hospital of Traditional Chinese Medicine， Capital Medical University

The First Affiliated Hospital of Henan University of Chinese Medicine

Collaborative Innovation Center for Chinese Medicine and Respiratory Diseases Co-constructed by Henan Province and Education Ministry of P.R. China/Henan Key Laboratory of Chinese Medicine for Respiratory Disease，Henan University of Chinese Medicine

The First Clinical Medical School of Henan University of Chinese Medicine

The First Clinical College of Nanjing University of Chinese Medicine

AI问答

Postal code：100700
Tel：010-84076882 Email：syfjx_2010@188.com
Technical support is provided by Beijing Founder electronics co., LTD 京ICP备11006657号-10 京公网安备11010802024621
It is recommended to read the content of this site in Chrome&IE9+. Please switch to extreme mode in browser 360.
Cookies We use cookies to help provide and enhance our service and tailor content. By continuing, you agree to the use of cookies.

⁰